Oncimmune Holdings PLC PDMR Dealing (0688J)

TIDMONC

RNS Number : 0688J

Oncimmune Holdings PLC

07 April 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Matthew Hall, PDMR and Chief Financial Officer, has purchased 9,487 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") for GBP0.527 per share on 7 April 2020.

Following this transaction, Matthew has a total interest in the Company of 9,487 Ordinary Shares, representing approximately 0.01 per cent of the Company's issued Ordinary Share capital.

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                               Matthew Hall 
      ---------------------------------  -------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------- 
 a)    Position/status                    Chief Financial Officer 
      ---------------------------------  -------------------------------------- 
 b)    Initial                            Initial notification 
        notification 
        /Amendment 
      ---------------------------------  -------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------- 
 a)    Name                               Oncimmune Holdings plc 
      ---------------------------------  -------------------------------------- 
 b)    LEI                                213800HCYIWT6YPI1I02 
      ---------------------------------  -------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------- 
 a)    Description                        Ordinary Shares of GBP0.01 each 
        of the 
        financial 
        instrument, 
        type 
        of instrument 
 
       Identification                     ISIN: GB00BYQ94H38 
        code 
 
 b)    Nature                             Purchase of shares 
        of the 
        transaction 
      ---------------------------------  -------------------------------------- 
 c)    Price(s) 
        and volume(s) 
                                          --------------------  ------------- 
                                           Price                 Volume 
                                          --------------------  ------------- 
    GBP0.527                                                     9,487 
   -----------------------------------------------------------  ------------- 
 
 d)    Aggregated 
        information 
 
  - Aggregated                       Same as above 
   volume 
 
  - Price 
 
 e)    Date                               7 April 2020 
        of the 
        transaction 
      ---------------------------------  -------------------------------------- 
 f)    Place                              London stock exchange, AIM 
        of the 
        transaction 
      ---------------------------------  -------------------------------------- 
 

For further information:

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

[e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHKKOBQKBKDKQK

(END) Dow Jones Newswires

April 07, 2020 06:41 ET (10:41 GMT)